NEW YORK, June 27 (GenomeWeb News) - Affymetrix granted Epigenomics non-exclusive access to its microarray technology to develop microarray-based in vitro diagnostic tests for oncology, Epigenomics said today.
Epigenomics said the agreement complements its strategic alliance with Qiagen for sample preparation, announced last year.
Epigenomics will use the technologies to develop a platform for pathology tests based on its proprietary DNA methylation methods. Epigenomics will first develop pathology tests in prostate and breast cancer, the company said.
The company plans to transfer its molecular classification test for prostate cancer onto the Affymetrix platform to use it in clinical trials for FDA approval of the assay, scheduled to start next year.